Next-Generation Sequencing Approaches in Cancer: Where Have They Brought Us and Where Will They Take Us?

Next-generation sequencing (NGS) technologies and data have revolutionized cancer research and are increasingly being deployed to guide clinicians in treatment decision-making. NGS technologies have allowed us to take an “omics” approach to cancer in order to reveal genomic, transcriptomic, and epig...

Full description

Bibliographic Details
Main Authors: LeBlanc, Veronique G., Marra, Marco A.
Format: Online
Language:English
Published: MDPI 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4586802/
id pubmed-4586802
recordtype oai_dc
spelling pubmed-45868022015-10-06 Next-Generation Sequencing Approaches in Cancer: Where Have They Brought Us and Where Will They Take Us? LeBlanc, Veronique G. Marra, Marco A. Review Next-generation sequencing (NGS) technologies and data have revolutionized cancer research and are increasingly being deployed to guide clinicians in treatment decision-making. NGS technologies have allowed us to take an “omics” approach to cancer in order to reveal genomic, transcriptomic, and epigenomic landscapes of individual malignancies. Integrative multi-platform analyses are increasingly used in large-scale projects that aim to fully characterize individual tumours as well as general cancer types and subtypes. In this review, we examine how NGS technologies in particular have contributed to “omics” approaches in cancer research, allowing for large-scale integrative analyses that consider hundreds of tumour samples. These types of studies have provided us with an unprecedented wealth of information, providing the background knowledge needed to make small-scale (including “N of 1”) studies informative and relevant. We also take a look at emerging opportunities provided by NGS and state-of-the-art third-generation sequencing technologies, particularly in the context of translational research. Cancer research and care are currently poised to experience significant progress catalyzed by accessible sequencing technologies that will benefit both clinical- and research-based efforts. MDPI 2015-09-23 /pmc/articles/PMC4586802/ /pubmed/26404381 http://dx.doi.org/10.3390/cancers7030869 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author LeBlanc, Veronique G.
Marra, Marco A.
spellingShingle LeBlanc, Veronique G.
Marra, Marco A.
Next-Generation Sequencing Approaches in Cancer: Where Have They Brought Us and Where Will They Take Us?
author_facet LeBlanc, Veronique G.
Marra, Marco A.
author_sort LeBlanc, Veronique G.
title Next-Generation Sequencing Approaches in Cancer: Where Have They Brought Us and Where Will They Take Us?
title_short Next-Generation Sequencing Approaches in Cancer: Where Have They Brought Us and Where Will They Take Us?
title_full Next-Generation Sequencing Approaches in Cancer: Where Have They Brought Us and Where Will They Take Us?
title_fullStr Next-Generation Sequencing Approaches in Cancer: Where Have They Brought Us and Where Will They Take Us?
title_full_unstemmed Next-Generation Sequencing Approaches in Cancer: Where Have They Brought Us and Where Will They Take Us?
title_sort next-generation sequencing approaches in cancer: where have they brought us and where will they take us?
description Next-generation sequencing (NGS) technologies and data have revolutionized cancer research and are increasingly being deployed to guide clinicians in treatment decision-making. NGS technologies have allowed us to take an “omics” approach to cancer in order to reveal genomic, transcriptomic, and epigenomic landscapes of individual malignancies. Integrative multi-platform analyses are increasingly used in large-scale projects that aim to fully characterize individual tumours as well as general cancer types and subtypes. In this review, we examine how NGS technologies in particular have contributed to “omics” approaches in cancer research, allowing for large-scale integrative analyses that consider hundreds of tumour samples. These types of studies have provided us with an unprecedented wealth of information, providing the background knowledge needed to make small-scale (including “N of 1”) studies informative and relevant. We also take a look at emerging opportunities provided by NGS and state-of-the-art third-generation sequencing technologies, particularly in the context of translational research. Cancer research and care are currently poised to experience significant progress catalyzed by accessible sequencing technologies that will benefit both clinical- and research-based efforts.
publisher MDPI
publishDate 2015
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4586802/
_version_ 1613481385125740544